Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Montreal Heart Institute
Age
19–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
male or female greater than 18 years of age. Female subjects must be post-menopausal (defined as two years after menstrual cycle)
within normal range for the following: BP systolic 100-140 mmHg and diastolic 50-90 mmHg;
HR 60-100 beats per minute;
oral temperature less than 37.6 degrees Centigrade;
respiratory rate 12-20 breaths per minute;
normal lung function tests;
normal echocardiogram including estimation of pulmonary artery systolic pressure;
normal chest x-ray; Normal electrocardiogram
You may not be if
any known chronic or acute medical condition with or without the need for chronic pharmacologic therapy or any condition that may interfere with normal biodistribution of DFH-12. Includes but not limited to:
* lung parenchymal or lung vascular diseases such as chronic obstructive pulmonary disease,
* bronchitis,
* lung cancer,
* pleural effusion,
* emphysema,
* asthma,
* pulmonary fibrosis,
* occupational lung disease,
* pulmonary hypertension (primary or secondary),
* systemic hypertension,
* diabetes,
* cancer,
* kidney disease,
* liver disease,
* heart failure or previous myocardial infarction,
* coronary artery disease,
* peripheral vascular disease or inflammatory disease;
subjects requiring chronic administration of any substance for a medical condition, active smoking or history of smoking for more than one year in the past 10 years, known self-reported alcoholism (active or abstinent);
unable to tolerate study procedures ex.(venipuncture, movement restrictions during imaging);
previous nuclear study since one week (to avoid cross-contamination)
Clareo Health | Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation
